ly 293558 has been researched along with lofepramine hydrochloride in 6 studies
| Studies (ly 293558) | Trials (ly 293558) | Recent Studies (post-2010) (ly 293558) | Studies (lofepramine hydrochloride) | Trials (lofepramine hydrochloride) | Recent Studies (post-2010) (lofepramine hydrochloride) |
|---|---|---|---|---|---|
| 103 | 4 | 18 | 17 | 0 | 1 |
| Protein | Taxonomy | ly 293558 (IC50) | lofepramine hydrochloride (IC50) |
|---|---|---|---|
| Integrin beta-3 | Homo sapiens (human) | 0.35 | |
| Integrin alpha-IIb | Homo sapiens (human) | 0.35 | |
| Glutamate receptor 1 | Rattus norvegicus (Norway rat) | 0.3371 | |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | 0.3371 | |
| Glutamate receptor 3 | Rattus norvegicus (Norway rat) | 0.3371 | |
| Glutamate receptor 4 | Rattus norvegicus (Norway rat) | 0.3371 | |
| Glutamate receptor ionotropic, kainate 1 | Rattus norvegicus (Norway rat) | 0.28 | |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 10 | |
| Glutamate receptor ionotropic, kainate 2 | Rattus norvegicus (Norway rat) | 0.28 | |
| Glutamate receptor ionotropic, kainate 3 | Rattus norvegicus (Norway rat) | 0.28 | |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 10 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 10 | |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 10 | |
| Glutamate receptor ionotropic, kainate 4 | Rattus norvegicus (Norway rat) | 0.28 | |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 10 | |
| Glutamate receptor ionotropic, kainate 5 | Rattus norvegicus (Norway rat) | 0.28 | |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 10 | |
| P2Y purinoceptor 12 | Homo sapiens (human) | 0.35 | |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 10 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boireau, A; Chevé, M; Damour, D; Genevois-Borella, A; Imperato, A; Jimonet, P; Mignani, S; Pratt, J; Randle, JC; Ribeill, Y; Stutzmann, JM | 1 |
| Bohme, GA; Boireau, A; Damour, D; Debono, MW; Genevois-Borella, A; Imperato, A; Jimonet, P; Mignani, S; Pratt, J; Randle, JC; Ribeill, Y; Stutzmann, JM; Vuilhorgne, M | 1 |
| Bohme, GA; Boireau, A; Damour, D; Debono, MW; Genevois-Borella, A; Jimonet, P; Mignani, S; Pratt, J; Randle, JC; Ribeill, Y; Stutzmann, JM; Vuilhorgne, M | 2 |
| Bohme, GA; Boireau, A; Bouquerel, J; Damour, D; Debono, MW; Genevois-Borella, A; Hardy, JC; Hubert, P; Jimonet, P; Manfré, F; Mignani, S; Nemecek, P; Pratt, J; Randle, JC; Ribeill, Y; Stutzmann, JM; Vuilhorgne, M | 1 |
| Carcache, D; Kalkman, HO; Koller, M; Mattes, H | 1 |
6 other study(ies) available for ly 293558 and lofepramine hydrochloride
| Article | Year |
|---|---|
Spiro-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one derivatives are mixed AMPA and NMDA glycine-site antagonists active in vivo.
Topics: Animals; Binding Sites; Excitatory Amino Acid Antagonists; Glycine; Mice; Pyrazines; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Spiro Compounds; Structure-Activity Relationship | 1999 |
4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activity.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Drug Evaluation, Preclinical; Inhibitory Concentration 50; Isoquinolines; Mice; Mice, Inbred DBA; Pyrazines; Quinoxalines; Rats; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Structure-Activity Relationship; Tetrazoles; Urea | 2000 |
Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]inden.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Brain; Cell Membrane; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Routes; Excitatory Amino Acid Agonists; Heterocyclic Compounds, 4 or More Rings; Imidazoles; Inhibitory Concentration 50; Male; Mice; Mice, Inbred DBA; Oocytes; Protein Binding; Pyrazines; Rats; Receptors, AMPA; Seizures; Structure-Activity Relationship; Time Factors; Xenopus | 2000 |
Bioisosteres of 9-carboxymethyl-4-oxo-imidazo[1,2-a]indeno-[1,2-e]pyrazin-2-carboxylic acid derivatives. Progress towards selective, potent in vivo AMPA antagonists with longer durations of action.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Combinatorial Chemistry Techniques; Disease Models, Animal; Excitatory Amino Acid Antagonists; Imidazoles; Inhibitory Concentration 50; Male; Mice; Oocytes; Pyrazinamide; Pyrazines; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Seizures; Structure-Activity Relationship | 2001 |
Synthesis of anticonvulsive AMPA antagonists: 4-oxo-10-substituted-imidaz.
Topics: Animals; Anticonvulsants; Carboxylic Acids; Dose-Response Relationship, Drug; Electroshock; Injections, Intraperitoneal; Injections, Intravenous; Isoquinolines; Mice; Pyrazines; Quinoxalines; Rats; Receptors, AMPA; Structure-Activity Relationship; Tetrazoles; Xenopus | 2001 |
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside.
Topics: Analgesics; Animals; Anticonvulsants; Antipsychotic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Neuroprotective Agents; Protein Subunits; Receptors, AMPA | 2010 |